Skip to main content

Carfilzomib with or without Romidepsin in Treating Patients with Stage IA-IVB Cutaneous T-Cell Lymphoma

Trial Status: Active

This randomized phase I trial studies the side effects and the best dose of carfilzomib when given together with or without romidepsin in treating patients with stage IA-IVB cutaneous T-cell lymphoma. Carfilzomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving carfilzomib alone is more effective than when given together with romidepsin.

Inclusion Criteria

  • Patients must have histological confirmation of a cutaneous T-cell lymphoma (CTCL) of any histology; confirmation of histological diagnosis must be completed prior to enrollment by the lead site (Northwestern) * Patients will be stratified by mycosis fungoides (MF) and Sezary syndrome (SS) (report diagnostic or consistent with MF/SS), stage IA-IVB according to TNM blood (TNMB) classification versus other CTCL histologies
  • Patients must have measurable disease (using modified Severity-Weighted Assessment Tool [mSWAT]) and/or use of indicator lesions must be designated prior to study enrollment (from imaging); measurable disease upon physical exam with a negative scan is acceptable
  • Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
  • Patients must have a life expectancy of >= 3 months
  • Patients must be refractory or intolerant to at least 1 prior standard systemic therapy, if a candidate for systemic therapy
  • Patients with MF/SS must have failed at least 1 prior topical therapy (including steroids, nitrogen mustard, retinoids, phototherapy, photochemotherapy, radiation, and total skin electron beam); there is no upper limit for prior therapies
  • Non-MF/SS patients who are candidates for topical therapy must be refractory or intolerant to at least 1 prior topical therapy
  • Serum creatinine =< 2.0 mg/dL
  • Total bilirubin =< 2.2 mg/dL
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x upper limit of normal (ULN)
  • Leukocytes >= 3,000/mm^3
  • Absolute neutrophils >= 1,500/mm^3
  • Platelets >= 100,000/mm^3
  • Patients must have an electrocardiogram (EKG) within 28 days prior to registration according to the following parameters: * Male patients must have a corrected QT (QTc) =< 450 ms * Female patients must have a QTc =< 470 ms
  • Females of child-bearing potential and sexually active males must agree to use effective methods of contraception: * Child-bearing potential is defined as any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has NOT undergone a hysterectomy or bilateral oophorectomy; OR ** Has NOT been naturally menopausal for at least 12 consecutive months (i.e. has had menses at any time in the preceding 12 consecutive months) * Effective methods should include at least 1 form of barrier contraception
  • Females of child-bearing potential must have a negative pregnancy test within 7 days prior to registration
  • Patients must be disease free of any prior malignancies for >= 3 years * The exception to this would be currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage 0) with histologically confirmed free margins of excision
  • Patients must give written informed consent prior to registration on the study

Exclusion Criteria

  • Patients who have received topical therapy, systemic chemotherapy, or biological therapy within 4 weeks prior to registration are NOT eligible for participation
  • Patients who have undergone major surgery within 21 days prior to registration are NOT eligible for participation
  • Patients who have an acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to registration are NOT eligible for participation
  • Patients in whom IV fluid hydration is contraindicated (e.g. due to pre-existing pulmonary, cardiac, or renal impairment) will NOT be eligible for participation
  • Patients who are pregnant and/or lactating are NOT eligible for participation
  • Patients who have had a prior stem cell transplantation are NOT eligible for participation
  • Patients who have had any of the following cardiac conditions are NOT eligible for participation (unless otherwise noted): * Unstable angina or myocardial infarction within 4 months prior to registration * New York Heart Association (NYHA) class III or IV heart failure * Uncontrolled angina * A history of severe coronary artery disease * Severe, uncontrolled ventricular arrhythmias * Sick sinus syndrome * Electrocardiographic evidence of acute ischemia or grade 3 conduction system abnormalities UNLESS the patient has a pacemaker
  • Patients who exhibit uncontrolled hypertension (>= 140/90 mmHg) or uncontrolled diabetes within 14 days prior to registration are NOT eligible for participation
  • Patients who have experienced significant neuropathy (grades 3-4 or grade 2 with pain) within 14 days prior to registration are NOT eligible for participation
  • Patients who have a known history of allergy to Captisol (a cyclodextrin derivative used to stabilize carfilzomib) are NOT eligible for participation
  • Patients who have a contraindication to any of the required concomitant drugs or supportive treatments (including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment) are NOT eligible for participation
  • Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to registration are NOT eligible for participation
  • Patients who have any serious condition, laboratory abnormality, or psychiatric illness that would prevent them from singing the informed consent form are NOT eligible for participation
  • Patients who have had prior exposure to romidepsin or any proteasome inhibitor are NOT eligible for participation
  • Patients with a known human immunodeficiency virus (HIV) infection are NOT eligible for participation
  • Patients who test positive for infectious hepatitis types A, B, or C within 14 days of registration are NOT eligible for participation


Palo Alto
Stanford Cancer Institute Palo Alto
Contact: Youn H Kim
Phone: 650-498-6000


Emory University Hospital / Winship Cancer Institute
Contact: Mary Jo Lechowicz
Phone: 404-778-3908


Northwestern University
Contact: Barbara Pro
Phone: 312-695-0321


Saint Louis
Washington University School of Medicine
Contact: Kenneth Robert Carson
Phone: 314-362-0493

New York

New York
Memorial Sloan Kettering Cancer Center
Contact: Christiane Querfeld
Phone: 212-610-0758


I. To determine the maximum tolerated dose (MTD) of carfilzomib, both as a single agent as well as in combination with romidepsin, in patients with cutaneous T-cell lymphoma (CTCL).


I. Overall response rate (ORR).

II. Duration of response.

III. Time to progression (TTP).


I. Measure proteasome activity concurrently in peripheral blood mononuclear cells (PBMCs) and tumor tissue biopsy specimens in order to gather pilot data on proteasome inhibition in CTCL patients treated with carfilzomib alone as well as carfilzomib with romidepsin.

OUTLINE: This is a dose-escalation study of carfilzomib. Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive carfilzomib intravenously (IV) over 30 minutes on days 1, 2, 8, 9, 15, and 16.

ARM B: Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.

In both arms, treatment repeats every 28 days for at least 2-4 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at approximately 30 days and then every 3 months for up to 1 year.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Northwestern University

Principal Investigator
Barbara Pro

  • Primary ID NU 12H06
  • Secondary IDs NCI-2012-01952, IST-CAR-532, STU00071042, SP0021927
  • ID NCT01738594